So-called mature markets can grow: what changed in the UK turnaround
The starting point
When I took on the UK business at Watson-Marlow Fluid Technology Solutions, sales were under £10m and declining in real terms. The prevailing view was that the UK was a mature market and decline was inevitable.
Over the next ten years we grew sales to more than £25m, with orders peaking at £29m. By the end I was leading a 39-person team across sales, business development, account management, applications engineering, marketing and commercial operations, with full responsibility for the UK P&L.
Result | Figure |
|---|---|
UK sales | From under £10m to £25m+, orders peaking at £29m |
Sales growth (CAGR) | 10.2% over seven years |
Profit growth (CAGR) | 14.5% over five years |
UK commercial team | 39 people |
What changed
A sales business in its own right. The sales team had been embedded in factory operations. We separated it into a standalone UK sales operation with its own P&L, focus and accountability.
Specialists, not generalists. Instead of everyone selling everything to everyone, we evolved into three sector teams: Life Science (biopharma and medical devices), Sanitary Process (food, beverage and cosmetics) and Industrial Process (industrial, water and mining). It didn't happen overnight. Each sector had to grow enough to justify its own team before it became one.
New roles, new to the group. We introduced roles that had never been tried anywhere in the group: a Business Development Manager, a Key Account Manager and a Service Engineer.
Process and systems. We rebuilt the sales process, introduced proper pipeline management and upgraded the CRM, so performance became visible and predictable.
From transactional to consultative selling. Training, coaching and leadership development helped the team focus on understanding customers' applications and solving their problems, not just processing orders.
Growth beyond the core. We integrated acquired product lines and launched new products into the UK market.
Starting with Life Science
We didn't create all three sector teams at once. Life Science came first, because it had the critical mass and a range of products with strong value propositions.
It wasn't painless. Territories had to be redrawn, and some of the team had to hand over profitable pharma accounts they'd built up. Two things helped: the business backed the change, and the sector model had already been proven in the USA, albeit through a rep network rather than direct sales.
Once Life Science was working, the other sectors followed as each grew big enough to justify its own team.
What the numbers showed
We also split the P&L by sector, route to market and product group. It changed how we saw the business.
The most interesting finding was OEM. It had the lowest gross margin of any sector, so on paper it looked like the weakest. In fact it was the most profitable, because the business was repeat business: the same customers ordering again and again.
It went further. The OEM route fed a more profitable end-user market. Without the OEMs, we wouldn't have had the same end-user success.
The lesson: judge a customer or channel on its profitability and on what it leads to, not on gross margin alone.
"The transformation of our UK sales division exceeded all expectations. By creating a dedicated, specialized team with the right processes and culture, we turned a declining business into our fastest-growing region." — Leadership Team, Watson-Marlow Fluid Technology Solutions
What it means for a smaller business
Most of the businesses I work with are a fraction of that size, but the lesson carries. Growth didn't come from a better market. It came from structure: a clear sales function, people focused where they add most value, a visible pipeline and a regular rhythm.
Those are the same things a Profit Lever Workshop looks at, scaled to your business.
Want to see where your structure is holding growth back? Book a 30-minute Clarity Call.
